Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Translational Lung Cancer Research|February 10, 2023
Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort studyQi-Hua Zou, Hui Liu, Cai-Wen Huang, et al.Zhonghua Yi Xue Za Zhi|February 9, 2010
[Short and long-term outcomes of neoadjuvant chemotherapy for locally advanced esophageal carcinoma]Ming-ran Xie, Xu Zhang, Peng Lin, et al.Journal of Thoracic Disease|May 1, 2018
Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinomaXiang-Yang Yu, Xue-Wen Zhang, Fang Wang, et al.Plos One|April 24, 2015
The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer PatientsSha Fu, Ying Liang, Yong-Bin Lin, et al.Lung Cancer (Amsterdam, Netherlands)|November 9, 2015
Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinomaZe-Rui Zhao, Shao-Yan Xi, Wei Li, et al.AI Zheng = Aizheng = Chinese Journal of Cancer|August 4, 2007
[Influence of perioperative hypertension on postoperative cardiovascular complications in chest cancer patients]Yong-Nan Wang, Hao Long, Peng Lin, et al.Journal of Inflammation Research|August 14, 2023
Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant ImmunochemotherapyWen-Yu Zhai, Fang-Fang Duan, Yao-Bin Lin, et al.Medical Oncology (Northwood, London, England)|December 17, 2013
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistanceZe-Rui Zhao, Jin-Feng Wang, Yong-Bin Lin, et al.The Oncologist|March 16, 2019
Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation SequencingZe-Rui Zhao, Yao-Bin Lin, Calvin S H Ng, et al.Journal of Thoracic Disease|December 23, 2017
Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survivalKe-Xing Xi, Ying-Sheng Wen, Chong-Mei Zhu, et al.Pageof 3